Cladribine Efficacy in a Patient with Hairy Cell Leukemia and Severe Renal Insufficiency

Rev Recent Clin Trials. 2023;18(4):300-303. doi: 10.2174/0115748871241817230919062313.

Abstract

Background: Hairy cell leukemia commonly presents with pancytopenia, indolent course, and predisposition as infectious complications. Current first-line therapeutic options are purine analogues, particularly cladribine, with a high percentage of complete responses and durable remissions. However, their use is poorly investigated in patients affected by severe chronic renal insufficiency.

Case presentation: Here, we describe a case of HCL in a 68-year-old man affected by multiple comorbidities, including severe chronic renal failure. After a course of interferon-α, the patient received therapy with Cladribine every other week, obtaining a complete hematological remission and improvement of renal function.

Discussion: With a different soft schedule of cladribine, the patient was treated adequately, obtaining a complete remission.

Conclusion: Cladribine can be administered with caution, even in patients with renal failure, with good results.

Keywords: HCL; Hairy cell leukemia; cladribine; patient; renal insufficiency; therapeutic..

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Agents* / therapeutic use
  • Cladribine / therapeutic use
  • Humans
  • Interferon-alpha / therapeutic use
  • Leukemia, Hairy Cell* / complications
  • Leukemia, Hairy Cell* / drug therapy
  • Male
  • Remission Induction

Substances

  • Cladribine
  • Antineoplastic Agents
  • Interferon-alpha